Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates

Metastatic urothelial cancer, associated with a poor prognosis, is still major cause of cancer-related death, with scarce options of effective treatment after progression to platinum-based chemotherapy and immunotherapy. The human epithelial growth factor receptor 2 (Her-2) has been identified as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Albarrán, Víctor, Rosero, Diana Isabel, Chamorro, Jesús, Pozas, Javier, San Román, María, Barrill, Ana María, Alía, Víctor, Sotoca, Pilar, Guerrero, Patricia, Calvo, Juan Carlos, Orejana, Inmaculada, Pérez de Aguado, Patricia, Gajate, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603928/
https://www.ncbi.nlm.nih.gov/pubmed/36293515
http://dx.doi.org/10.3390/ijms232012659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603928/
https://www.ncbi.nlm.nih.gov/pubmed/36293515
http://dx.doi.org/10.3390/ijms232012659

Ejemplares similares